NCT02442323 is a NA clinical trial of Walking Intervention in Cancer of Pancreas, sponsored by Fox Chase Cancer Center.

Who is sponsoring NCT02442323?

NCT02442323 is sponsored by Fox Chase Cancer Center.

What drugs are being tested in NCT02442323?

Interventions in NCT02442323: Walking Intervention.

What condition does NCT02442323 study?

NCT02442323 studies Cancer of Pancreas.

Is NCT02442323 still recruiting?

NCT02442323 is currently completed. Last updated 5 January 2021.

Last reviewed 2021-01-05 · How we verify

NCT02442323

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients

Completed NA Last updated 5 January 2021

What this trial tests

NA trial testing Walking Intervention in Cancer of Pancreas in 50 participants. Completed in 30 November 2020.

Timeline

9 August 2013

Primary endpoint
30 August 2020

30 November 2020

Quick facts

Lead sponsor	Fox Chase Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	50
Start date	9 August 2013
Primary completion	30 August 2020
Estimated completion	30 November 2020
Sites	1 location across United States

Drugs / interventions tested

Walking Intervention

Conditions studied

Cancer of Pancreas — all drugs for Cancer of Pancreas →

Sponsor

Fox Chase Cancer Center — full company profile →

Who can join

18 and older, any sex, with Cancer of Pancreas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite evidence regarding the benefits of physical activity in various cancer patient populations, the effects of a home-based walking program for pancreatic cancer patients have been under-explored. The aims of the proposed pilot project are to: (1) Assess the feasibility of implementing a 12-week, home-based walking program among pancreatic cancer patients; and (2) Examine the effects of a 12-week, home-based walking program on quality of life (QOL) and symptoms among pancreatic cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer of Pancreas

Currently open trials in the same condition.

NCT06940778 — LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TU · active not recruiting
NCT05485974 — A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation · Phase 1 · active not recruiting
NCT06344507 — Iconographic Registry of Pancreatobiliary Endoscopy Procedures · recruiting
NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
NCT04677244 — Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level · NA · recruiting

Other Fox Chase Cancer Center trials

Trials by the same sponsor.

NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02442323 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
Last refreshed: 5 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02442323.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing